Reni Benjamin
Stock Analyst at Citizens
(1.36)
# 3,633
Out of 5,112 analysts
160
Total ratings
37.23%
Success rate
-12.95%
Average return
Main Sectors:
Stocks Rated by Reni Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPX Compass Therapeutics | Initiates: Market Outperform | $10 | $4.96 | +101.61% | 1 | Dec 3, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Market Outperform | $10 → $12 | $6.95 | +72.66% | 15 | Oct 31, 2025 | |
| ALLO Allogene Therapeutics | Reiterates: Market Perform | n/a | $1.42 | - | 8 | Aug 4, 2025 | |
| INBX Inhibrx Biosciences | Reiterates: Market Perform | n/a | $83.09 | - | 10 | May 15, 2025 | |
| CUE Cue Biopharma | Reiterates: Market Outperform | $2 | $0.40 | +400.00% | 5 | Apr 2, 2025 | |
| BCAB BioAtla | Maintains: Market Outperform | $5 → $1 | $0.78 | +27.80% | 9 | Mar 31, 2025 | |
| INCY Incyte | Reiterates: Market Perform | n/a | $97.63 | - | 28 | Mar 11, 2025 | |
| ACET Adicet Bio | Reiterates: Market Perform | n/a | $0.47 | - | 5 | Mar 7, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Market Outperform | $12 → $4 | $1.07 | +273.83% | 5 | Jan 14, 2025 | |
| CGEN Compugen | Maintains: Market Outperform | $8 → $4 | $1.52 | +163.16% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.27 | - | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $6.35 | - | 3 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $10 | $18.83 | -46.89% | 2 | Oct 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $5 | $4.78 | +4.60% | 6 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $28 | $10.18 | +175.05% | 11 | Jun 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $11.01 | - | 2 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $40 | $17.01 | +135.16% | 4 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.52 | - | 11 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $1.95 | +105.13% | 5 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $9.13 | - | 10 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $8 | $9.01 | -11.21% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $60 | $49.65 | +20.85% | 1 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $9.65 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $315 | $216.00 | +45.83% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $79.14 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $265 | $251.67 | +5.30% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $28 → $17 | $4.26 | +299.06% | 3 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | n/a | $13.17 | - | 4 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $1.61 | - | 2 | Feb 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $22 → $12 | $31.13 | -61.45% | 1 | Sep 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $22.62 | - | 1 | Nov 15, 2017 |
Compass Therapeutics
Dec 3, 2025
Initiates: Market Outperform
Price Target: $10
Current: $4.96
Upside: +101.61%
Bicycle Therapeutics
Oct 31, 2025
Maintains: Market Outperform
Price Target: $10 → $12
Current: $6.95
Upside: +72.66%
Allogene Therapeutics
Aug 4, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $1.42
Upside: -
Inhibrx Biosciences
May 15, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $83.09
Upside: -
Cue Biopharma
Apr 2, 2025
Reiterates: Market Outperform
Price Target: $2
Current: $0.40
Upside: +400.00%
BioAtla
Mar 31, 2025
Maintains: Market Outperform
Price Target: $5 → $1
Current: $0.78
Upside: +27.80%
Incyte
Mar 11, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $97.63
Upside: -
Adicet Bio
Mar 7, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $0.47
Upside: -
Werewolf Therapeutics
Jan 14, 2025
Maintains: Market Outperform
Price Target: $12 → $4
Current: $1.07
Upside: +273.83%
Compugen
Aug 8, 2022
Maintains: Market Outperform
Price Target: $8 → $4
Current: $1.52
Upside: +163.16%
Dec 3, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $1.27
Upside: -
Jun 14, 2019
Reinstates: Market Perform
Price Target: n/a
Current: $6.35
Upside: -
Oct 12, 2018
Maintains: Outperform
Price Target: $11 → $10
Current: $18.83
Upside: -46.89%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $5
Current: $4.78
Upside: +4.60%
Jun 4, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $10.18
Upside: +175.05%
Jun 2, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $11.01
Upside: -
Jun 2, 2025
Reiterates: Market Outperform
Price Target: $40
Current: $17.01
Upside: +135.16%
May 9, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $2.52
Upside: -
Apr 29, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $1.95
Upside: +105.13%
Mar 14, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $9.13
Upside: -
Mar 12, 2025
Maintains: Market Outperform
Price Target: $7 → $8
Current: $9.01
Upside: -11.21%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $60
Current: $49.65
Upside: +20.85%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $9.65
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $315
Current: $216.00
Upside: +45.83%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $79.14
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $265
Current: $251.67
Upside: +5.30%
Nov 10, 2020
Downgrades: Outperform
Price Target: $28 → $17
Current: $4.26
Upside: +299.06%
Jun 14, 2019
Reinstates: Outperform
Price Target: n/a
Current: $13.17
Upside: -
Feb 7, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $1.61
Upside: -
Sep 25, 2018
Downgrades: Outperform
Price Target: $22 → $12
Current: $31.13
Upside: -61.45%
Nov 15, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $22.62
Upside: -